(Reuters) - ArQule Inc and Japan's Daiichi Sankyo Co Ltd said a mid-stage trial of their colorectal cancer drug failed to meet the main study goal of improving patient survival without the cancer getting worse, sending ArQule's shares tumbling before the bell. ArQule shares were down 23 percent at $2.25 before the bell. They closed at $2.92 on Thursday on the Nasdaq. The trial, which enrolled 122 patients with refractory or relapsed colorectal cancer, also failed to meet the secondary goal of showing improved response to the drug. ... Courtesy of Yahoo News
No comments:
Post a Comment